Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 3, RANDOMIZED, DOUBLE BLIND, CONTROLLED, MULTI CENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB ADDED ON TO DICLOFENAC SR IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE OR HIP

NCT00864097 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00864097
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00864097 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 3, RANDOMIZED, DOUBLE BLIND, CONTROLLED, MULTI CENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB ADDED ON TO DICLOFENAC SR IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE OR HIP
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Terminated
Start date
August 11, 2009
Completion date
November 24, 2010
Enrollment
607 (actual)
Sites
77

Conditions

As the registry lists them; a condition with its own page is linked.

osteoarthritis